In Vivo is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Brought to you by

Sucampo, Takeda enter constipation drug deal

Executive Summary

Sucampo (R&D oriented biotech focusing on under-treated niche diseases) and Takeda will collaborate on the development of lubiprostone (SPI-0211), a late-stage compound in Sucampo's pipeline for indications in chronic constipation (completed Phase III) and constipation-predominant irritable bowel syndrome (completed Phase II).

Deal Industry
  • Biotechnology
  • Pharmaceuticals
Deal Status
  • Final
Deal Type
  • Alliance
    • R&D and Marketing (Licensing)

Related Companies